95P - The role of surgery in combination treatment of patients with small cell lung cancer

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Anticancer agents
Small Cell Lung Cancer
Surgical Oncology
Biological Therapy
Radiation Oncology
Presenter Aleksei Aksarin
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors A.A. Aksarin1, M.D. Ter-Ovanesov2, A.M. Parsadanyan3, S.M. Kopeyka1, A.A. Mordovskiy1
  • 1Oncology Center, Surgut District Clinical Hospital, 628408 - Surgut/RU
  • 2Department Of Oncology And Haematology, N.I. Pirogov Russian National Research Medical University, 117997 - Moscow/RU
  • 3Department Of Oncology, Surgut State University, 628412 - Surgut/RU



Small cell lung cancer (SCLC) as the most aggressive tumor deserves a special attention. The aim of this research was to define the place of surgery of patients with SCLC in order to improve the results of treatment.


Clinical material for research consists of 45 patients in stage IA-IIIA with SCLC, which were radically operated in Ugra (region Russia) between 1999 and 2012. Among patients predominate males 37 (82.2%), versus females – eight (17.8%).


All patients underwent radical operations R0. All resection types were included (pneumonectomy, bilobectomy, and lobectomy). By 31 patients (68.9%) systematic nodal dissection (SND) was carried out, by 5 (11.1%) – mediastinal lymph node sampling (MLS) and by 9 patients mediastinal node dissection was not carried out. By SCLC combination treatment was used more often – 31 (68.9%). By that only in 8 cases additional adjuvant of thoracic radiotherapy was used. In 14 cases only surgical resection was used (31.1%). 5-year overall survival (OS) rate was 47.1%. Median survival rate was 58 months. Five-year OS rate by surgery combined with adjuvant chemotherapy was 52.1%, as compared to only surgical treatment – 35.6%. At I stage satisfactory results were achieved: 5-year OS rate was 69% (p 


SCLC at I and II stages is the indication to radical treatment, mandatory including surgical resection with SND and adjuvant chemotherapy. The main method of treatment at III stage is chemotherapy or chemoradiotherapy.

Clinical trial identification


Legal entity responsible for the study

Surgut District Clinical Hospital, Surgut, Russia


Surgut District Clinical Hospital, Surgut, Russia


All authors have declared no conflicts of interest.